Epinephrine Auto-Injector Market Is Expected To Grow At A CAGR Of 8% During The Forecast Period 2020–2025

The epinephrine auto-injector market is expected to grow at a CAGR of over 8% during the period 2019–2025. The global epinephrine auto-injector market is expected to grow at a steady rate during the forecast period. The growth can be mainly attributed to the growing prevalence of anaphylaxis across demographics. Anaphylaxis is characterized as a potentially life-threatening systemic allergic reaction, which is most commonly triggered by medication, food allergies, or insect stings. In developed countries such as the US and the UK, the incidence of anaphylaxis is 40–500 per million persons. Anaphylaxis-associated mortality is estimated at 0.63–0.76 per million. In the US, up to 5% population suffers from this condition. Over the last several years, a rising number of clinical databases such as PubMed have captured the growing prevalence of anaphylaxis. Globally, allergies caused by food items, food additives, latex, and dust are increasing at a steady rate. Such allergies, including anaphylaxis, are the most commonly prevalent in industrially developed countries such as the US and the UK. Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of epinephrine as it the first-aid treatment option, thereby driving the global market.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-91085

“The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market).”

Key Vendors

• Mylan
• Teva Pharmaceutical Industries
• Amneal Pharmaceuticals• Adamis Pharmaceuticals
• ALK-Abelló
• Bioprojet PHARMA
• Bausch & Lomb
• kaléo
• Novartis


The global epinephrine auto-injector market is highly consolidated and is characterized by the presence of a few established vendors holding the majority of the market share. Vendors are offering several branded as well as generic epinephrine auto-injectors and are competing based on factors in terms of regulatory approvals, safety features, accurate dosing, convenience, technology, marketing strategies, and distribution channels.

The following factors are likely to contribute to the growth of the epinephrine auto-injector market during the forecast period:

• Emergence of Innovative Solutions for Anaphylaxis Management
• Increasing Demand for Generic Epinephrine Auto-injectors at Pharma/Retail Stores
• Growing Demand for Self-administration of Drugs
• Availability of Generic Versions of Auto-injectors


This research report includes a detailed segmentation by dosage, age group, end-user, and geography. The growing incidence of anaphylaxis in adults, especially in the elderly population, is the primary factor driving the growth of the high dose segment. As epinephrine is considered as the first-line treatment for anaphylaxis, the increasing recommendation of high dose by healthcare professionals (HCP) across the globe for adult patients is fueling the growth of the segment. Moreover, market players are also focusing on providing generic, low-cost products, which are increasing the demand for affordable treatment options for managing anaphylactic reactions.

Several social and emotional factors contribute to the high prevalence of anaphylaxis in teenage and adult groups, including risk-taking behaviors with eating and disease denial. Adults with peanut allergy have more severe reactions than children. HCPs recommend a high as well as safe dose (usually 0.3 mg) of epinephrine auto-injectors to the patient group aged 12 years and above. Furthermore, anaphylaxis in the elderly population tends to be life-threatening and requires intensified medical intervention. Therefore, managing the high risk of anaphylaxis in this group, especially in elderly people, is expected to drive the uptake of epinephrine auto-injectors.

The burden of anaphylaxis among children is growing, hence it requires quick and effective management. Government and regulatory bodies are providing safeguards to prevent fatal reactions among children in the 6–12 years age group. Epinephrine through auto-injectors acts fast and can rapidly treat the most dangerous symptoms in children, including throat swelling, difficulty breathing, and low blood pressure. Thus, it is always been recommended to make ready epinephrine auto-injectors for children in schools to avoid fatal conditions due to anaphylaxis, thereby driving the segment growth.

In 2019, the below 6 years segment accounted for a 10% market share of the global epinephrine auto-injector market. Children in this age group are prescribed to be treated with 0.15 mg/0.1 mg dose capacity. An estimated 130% increase in emergency room visits for anaphylaxis among children aged 4 years old and younger reported between 2005 and 2014. Since the management of anaphylaxis in this age group is becoming a major concern among HCPs and parents, vendors are focusing on introducing low-cost epinephrine auto-injectors for this age group.

The individual end-user segment accounted for the highest share in 2019. The segment is likely to grow with the highest growth rate mainly due to the growing demand for self-management of anaphylaxis. Individuals carry epinephrine auto-injectors for the treatment of sudden anaphylaxis shock. As the prevalence is growing rapidly worldwide, self-management is becoming increasingly important. Hence, the segment is likely to emerge as a major revenue generator during the forecast period.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-91085

“The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market).”

HCPs in hospitals & clinics are using epinephrine auto-injectors for the emergency management of anaphylaxis. The market is growing at a healthy rate on account of the high adoption of these devices by emergency departments in hospitals and clinics. The availability of skilled HCPs with knowledge and expertise also attracts many patients to hospitals and clinics. Large and medium-sized hospitals are equipped with sophisticated healthcare infrastructure for emergency management of anaphylaxis. Hence, the share of this segment is likely to grow at a steady growth during the forecast period.

Table of Content

1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusion
4.1.2 Exclusion
4.2 Base Year
4.3 Scope of The Study
4.4 Market Segments
4.4.1 Market Segmentation by Dosage
4.4.2 Market Segmentation by Age Group
4.4.3 Market Segmentation by End-user
4.4.4 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

The study considers the present scenario of the epinephrine auto-injector market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspect of the market. It profiles and examines leading companies and other prominent companies operating in the market.


The analysis of the epinephrine auto-injector market provides sizing and growth opportunities for the period 2019–2025.
• Offers sizing and growth prospects of the market for the forecast period 2020–2025.
• Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market.
• Includes a detailed analysis of growth drivers, challenges, and investment opportunities.
• Delivers a complete overview of segments and the regional outlook of the market.
• Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain competitive advantage.

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Shibuya Data Count
Email: sales@sdki.jp
Tel: + 81 3 45720790

Related Reports:

Poland: Handbags Market
Norway: Handbags Market
North Macedonia: Handbags Market
Netherlands: Handbags Market
Montenegro: Handbags Market 
Malta: Handbags Market 
Luxembourg: Handbags Market
Lithuania: Handbags Market
Latvia: Handbags Market 

Share your love
Christophe Rude

Christophe Rude

Articles: 15889

Leave a Reply

Your email address will not be published. Required fields are marked *